Evidence map›Paper›PMID 41809260›Full record

ReviewAsian journal of pharmaceutical sciences2025

Metal-organic frameworks as therapeutic chameleons: revolutionizing the cancer therapy employing novel nanoarchitectonics.

Sajja Bhanu Prasad, Akshay Shinde, Dadi A Srinivasrao, Paras Famta, Saurabh Shah, Tejaswini Kolipaka, Giriraj Pandey, Deelip Gaonker, Ganesh Vambhurkar, Pooja Khairnar and 4 more

Abstract readReview
In one paragraph

Review in Asian journal of pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sajja Bhanu PrasadDepartment of Pharmaceutics, Pharmaceutical Innovation and Translational Research Lab (PITRL), National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, India.
Akshay ShindeDepartment of Pharmaceutics, Pharmaceutical Innovation and Translational Research Lab (PITRL), National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, India.
Dadi A SrinivasraoDepartment of Pharmaceutics, Pharmaceutical Innovation and Translational Research Lab (PITRL), National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, India.
Paras FamtaDepartment of Pharmaceutics, Pharmaceutical Innovation and Translational Research Lab (PITRL), National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, India.
Saurabh ShahDepartment of Pharmaceutics, Pharmaceutical Innovation and Translational Research Lab (PITRL), National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, India.
Tejaswini KolipakaDepartment of Pharmaceutics, Pharmaceutical Innovation and Translational Research Lab (PITRL), National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, India.
Giriraj PandeyDepartment of Pharmaceutics, Pharmaceutical Innovation and Translational Research Lab (PITRL), National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, India.
Deelip GaonkerDepartment of Pharmaceutics, Pharmaceutical Innovation and Translational Research Lab (PITRL), National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, India.
Ganesh VambhurkarDepartment of Pharmaceutics, Pharmaceutical Innovation and Translational Research Lab (PITRL), National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, India.
Pooja KhairnarDepartment of Pharmaceutics, Pharmaceutical Innovation and Translational Research Lab (PITRL), National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, India.
Rahul KumarDepartment of Biological Sciences, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, India.
Amol G DikundwarDepartment of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, India.
Vinaykumar KanchupalliDepartment of Process Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, India.
Saurabh SrivastavaDepartment of Pharmaceutics, Pharmaceutical Innovation and Translational Research Lab (PITRL), National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is one of the most complex diseases and the second leading cause of mortality worldwide. Due to its poor prognosis and challenges in diagnosis, eradicating cancer remains highly difficult. The limitations associated with conventional therapies have led to the emergence of copious therapeutic strategies such as chemotherapy, phototherapy, starvation therapy, radiotherapy and immunotherapy; however, limited therapeutic efficacy, poor tumor cell selectivity and substantial adverse effects remain significant concern. Attributed to the expeditious advancement of nanotechnology, the amalgamation of nanomaterials with therapeutic approaches provides an opportunity to address the shortcomings of conventional chemotherapy. Metal-organic frameworks (MOFs), which consist of bridging ligands and ions/clusters connected by coordination bonds, have been widely used in cancer therapy to address the limitations of currently therapeutic interventions, such as poor efficacy, low stability and severe side effects. This potential arises from their tuneable porosities, high specific surface area-to-volume ratio, tailorable diameters, tractable morphologies, variegated compositions, biocompatibility and facile functionalization. We summarized the role of MOF-based nanoplatforms along with mechanistic insights into emerging avenues-such as cuproptosis, ferroptosis, cell-penetrating and biomimetic MOFs, and tumor microenvironment-responsive MOFs- alongside recent advancements in mono- and multifunctional cancer therapeutics. Theragnostic and imaging functionalities, as well as regulatory considerations and future prospects of MOF-based nanoplatforms utilized in cancer treatment, are also discussed.

Indexed as

Combination therapyMetal-organic frameworksMonotherapeutic modalityMultifunctional mofsTheranostic and imaging functionalities

Identifiers

PMID41809260
PMCPMC12550169

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.